The study by Ritchie et al., 1 in this issue employs electronic health record data and DNA biobanks to identify several genomic variants previously implicated 2 3 in the variation of ECG parameters of cardiac conduction and diseases of cardiac conduction. So why is this study worthy of note?
Ever since Enthoven first named the QRS complex 4 , investigators have sought to define what constitutes a normal complex and the diagnostic and prognostic significance of deviations from the norm. The growing understanding that there is no categorical set of normal values, prompted population studies of (typically white and male) subjects numbering in the 100's. 5 and eventually tens of thousands 6 . These studies did generate a more robust set of reference values and did emphasize that the notion of normal vs. abnormal QRS was not appropriate and argued
for "an index of the possibility of normals or abnormals occurring at various levels" and "variations in electrocardiograms….considerably greater than the present standards would lead one to expect…" 5 Subsequent, larger population studies including clinical trial populations 7 8 with broader age and gender distributions revealed that variation in QRS characteristics in healthy individuals was larger than suspected. In parallel, several studies analyzed the clinical correlates of ECG features, For example in 1967, Pipberger et al 9 conducted what might today be called a "phenome scan" 10 11 . For each of the identified ECG measures, they scanned multiple constitutional features (e.g. obesity) and ethnicity to assess bias and correlation. Among their findings were the significant differences in QRS measures in African Americans, even when correcting for differences in the other constitutional features. Fifty years later, in the era of commodity-priced genotyping, cohort studies with tens of thousands of subjects have identified dozens of SNP's which appear to be associated with reproducible and highly significant variation in QRS duration as well as several disorders of cardiac conduction (e.g. atrioventricular block). 2, and did emphasize that the notion of normal vs. abnormal QRS was not appropr ria ia ate e e and nd nd a a arg rg rgue ue u d d
for "an index of the possibility of normals or abnormals occurring at various levels" and "v var ar aria ia iati ti tion on ns s s in in in ele le ect ct ctro r cardiograms….considerabl ly y y g gr reater than the e p prese se en n nt t standards would lead one e t to expect…" " " 5 5 S Sub ub ubse se equ qu q en en ent t, t, l lar ar rg ge ger po po opul lat ti ion st tu udi i ies es s in in ncl lud udi in ng g g cl clin in inic c cal al t t tri ri rial al p pop op o ul ul ula a atio o ons ns efforts laid the foundations for exploiting the low incremental costs of using EHR data to rapidly characterize and select study populations. As phenotyping and sample acquisition became the major costs in disease genomics studies 13 , the use of EHR's to create an instrumented health enterprise for genetic discovery research using the informational byproducts of healthcare delivery (i.e. clinical documentation) and banked or discarded clinical blood samples has become increasingly attractive. Multiple studies have shown this EHR-driven approach feasible, accurate and cost-effective 14 and several national funding agencies now support these studies internationally.
In this context, the contribution of the study by Ritchie et al., 1 is twofold. First, is the demonstration that EHR-driven phenotyping can be used to accurately select patients and reproduce genomic associations (principally pointing to the genes SCN5A and and SCN10A)
for conduction disorders in a manner that scales cost-effectively to much larger population studies. Specifically, the EHRs were used to identify healthy individuals, to quantify their ECG measures and select the corresponding genotypes for the same individuals. Second, are the insights provided by the hypothesis-free inversion of conventional genome-wide studies. That is, the investigators selected the most significant SNP's (with respect to QRS variation) and scanned the entirety of the diagnoses of all patients in the EHR to determine which diagnoses were enterprise for genetic discovery research using the informational byproducts of he he eal al lth thca ca c re re re delivery (i.e. clinical documentation) and banked or discarded clinical blood samples has become n ncr cr rea ea easi si sing ng gly ly ly a a attra ra act ct ctiv i e. Multiple studies have sho ho ow wn n n this EHR-dri rive v v n ap ap app p proach feasible, accurate an nd d d co c st-effec cti ti iv v ve 1 14 a and nd n s sev ev e e er eral a al n nat at a i io ion nal l fun n ndi i ing ag ag agenc ci cie es es n n no ow w s s sup p ppo port rt t t th he hese se se s stu tudi di dies es s n nte te tern rn nat at a io iona na nall ll lly. y.
In thi is s s co co cont nt ntex ex ext, t, t, t t the h c c con on ontr r rib ib ibut ut ti i ion on n o o of f f th th he e e st st tud ud udy y y by by b R R Rit it tch ch chie ie e e e et t t al l l., ., , 1 1 1 is is is t two wo w fo fo fold ld ld. . . There remain several important loose ends in this study. For example, members of underrepresented minorities were specifically excluded, even though there is at least a fifty-year history of ethnicity-specific variation in ECG characteristics. Because these same underrepresented minorities are often overrepresented in academic health centers, the same EHR-driven approach could be readily and rapidly used to study the genomic basis of those differences 16 . Also, this study relied heavily on billing codes rather than the fine-grained diagnostic assessment of clinicians. The systematic application of natural language processing techniques to codify the content of clinical notes in EHRs will minimize the biases and lack of nclude the full complexity of our patient populations, including their ethnic hete ter r roge g g ne ne neit it ty, y, y, polypharmacy and comorbidities. The report also anticipated redrawing the current categorical di iag ag agno no nost st stic ic ic o o or dise se ea as ase boundaries as multidimensi si sion on nal and/or prob bab a a ilis is sti ti tic c c measures that draw d di dire e ect c ly from th th he e euan an nti ita ta tati ti tive ve ve m m mea ea asu su sure res s a avai ila ab ble in in the e e i i inf nfo o orm ma mat ti tio on n co om mmo mo ons ns ns. Th Th he wo wo work k k o of f f a Ri Ri itc tc tchi hi hie e e et et a a al. l. l., , pr prov ov ovid ides es a a add ddit tio io iona na al l l ev ev evid iden en ence ce ce o o of f th th the e fe e eas asib ib i il il ilit it ity y y an an and d ef f ffi fi fica ca cacy cy cy o of f f th th the e e pr pr prec ec cisi io ion n n medicine mod od del el el. .
granularity that come from the use of billing data 17 . Most ambitiously, restructuring the phenome scan to include broader processes such as inflammation or thrombosis may help speed the genomic characterization of the endopathotypes 18 that underlie multiple diseases. 
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